- recruiting
IMMUNO-FIT Observational Study
This study looks at how immunotherapy for cancer affects your fitness, quality of life, and side effects. We want to see if being fitter helps you cope better and understand how your fitness changes during treatment. It's an observation study, so your cancer treatment won't change.
United Kingdom - active not recruitingPHASE2
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment
This study looks at combining two types of immunotherapy with an existing drug called olaparib for people with certain advanced solid cancers whose cancer has already been treated. It focuses on patients with specific gene changes that might make the treatment more effective.
France - ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steriod-refractory immune related adverse events after immune checkpoint inhibitor therapy - ECIR
This study is looking at a treatment called Extracorporeal Photopheresis (ECP) for people who have developed side effects from certain cancer medicines. It aims to see how safe ECP is and if it helps with problems like gut inflammation, lung inflammation, liver inflammation, or skin rashes.
Germany - active not recruitingPHASE2
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
This study looks at how a drug called omalizumab can help people with serious food allergies take part in a food desensitisation programme more quickly. It's for people aged 6-25 who are allergic to multiple foods.
Canada - recruitingPHASE2
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
This study looks at combining a treatment called faecal microbiota transplant (FMT) with standard immunotherapy (Atezolizumab/Bevacizumab) for advanced liver cancer. We want to see if FMT can help the immunotherapy work better and if it's safe.
Germany